Table 1.
Insurance | Entire Cohort n=8425 | Black Non-Hispanic Survivors n=417 | Hispanic Survivors n=477 | White Non-Hispanic Survivors n=7531 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Private n=6395 | Public n=640 | None n=1390 | Private n=256 | Public n=67 | None n=94 | Private n=296 | Public n=72 | None n=109 | Private n=5843 | Public n=501 | None n=1187 | |
Characteristics | % | % | % | % | % | % | % | % | % | % | % | % |
Gendera b c d | ||||||||||||
Male | 52.4 | 40.2 | 59.8 | 51.6 | 34.3 | 57.4 | 48.3 | 37.5 | 57.8 | 52.7 | 41.3 | 60.2 |
Female | 47.6 | 59.8 | 40.2 | 48.4 | 65.7 | 42.6 | 51.7 | 62.5 | 42.2 | 47.3 | 58.7 | 39.8 |
Educationa b c d | ||||||||||||
HS or less | 23.8 | 63.4 | 47.8 | 33.5 | 56.7 | 50.0 | 35.5 | 65.2 | 54.8 | 22.8 | 64.1 | 47.0 |
HS + some college | 76.2 | 36.6 | 52.2 | 66.5 | 43.3 | 50.0 | 64.5 | 34.8 | 45.2 | 77.2 | 35.9 | 53.0 |
Household incomea b c d | ||||||||||||
<$10,000 | 4.1 | 40.4 | 19.8 | 10.8 | 53.7 | 37.5 | 5.1 | 42.3 | 21 | 3.8 | 38.5 | 18.5 |
$10,000–$19,999 | 9.6 | 26.7 | 27.3 | 18.6 | 20.4 | 25.0 | 14.9 | 28.8 | 27.2 | 9.0 | 27.2 | 27.4 |
$20,000–$39,999 | 31.5 | 22.0 | 32.1 | 37.2 | 16.7 | 20.9 | 32.2 | 15.4 | 40.7 | 31.2 | 23.5 | 32.2 |
$40,000–$59,999 | 25.2 | 7.3 | 12.7 | 21.6 | 7.4 | 9.7 | 23.9 | 7.7 | 7.4 | 25.4 | 7.2 | 13.3 |
Over $60,000 | 29.6 | 3.6 | 8.1 | 11.8 | 1.8 | 6.9 | 23.9 | 5.8 | 3.7 | 30.6 | 3.6 | 8.6 |
Cancer diagnosisa c d | ||||||||||||
Leukemia | 29.0 | 26.2 | 34.9 | 25.0 | 22.4 | 22.3 | 38.5 | 31.9 | 44.9 | 28.7 | 25.9 | 35.1 |
CNS | 10.2 | 26.9 | 9.9 | 8.6 | 20.9 | 6.4 | 5.7 | 25.0 | 6.4 | 10.5 | 27.9 | 10.4 |
HL | 20.1 | 10.5 | 15.0 | 12.9 | 11.9 | 21.3 | 17.9 | 12.5 | 11.9 | 20.6 | 10.0 | 14.7 |
NHL | 9.3 | 5.8 | 11.1 | 11.7 | 4.5 | 5.3 | 9.5 | 6.9 | 9.2 | 9.2 | 5.8 | 11.7 |
Kidney (Wilms) | 6.3 | 5.3 | 7.1 | 12.9 | 10.4 | 10.6 | 4.7 | 4.2 | 9.2 | 6.1 | 4.8 | 6.7 |
Neuroblastoma | 3.9 | 3.8 | 4.0 | 3.5 | 3.0 | 4.3 | 4.1 | 2.8 | 0.9 | 3.9 | 4.0 | 4.3 |
Soft tissue sarcoma | 10.0 | 7.9 | 9.6 | 13.3 | 10.5 | 13.8 | 10.1 | 5.6 | 8.3 | 9.8 | 8.0 | 9.4 |
Bone cancer | 11.2 | 13.6 | 8.4 | 12.1 | 16.4 | 16.0 | 9.5 | 11.1 | 9.2 | 11.2 | 13.6 | 7.7 |
Age at interviewa c d | ||||||||||||
18 – 24 | 36.2 | 39.5 | 49.5 | 45.7 | 29.9 | 40.5 | 39.9 | 47.2 | 56.0 | 35.6 | 39.7 | 49.6 |
25 – 34 | 48.5 | 50.8 | 41.7 | 43.8 | 61.1 | 48.9 | 47.6 | 47.2 | 35.7 | 48.8 | 49.9 | 41.7 |
35 + | 15.3 | 9.7 | 8.8 | 10.5 | 9.0 | 10.6 | 12.5 | 5.6 | 8.3 | 15.6 | 10.4 | 8.7 |
Grade 3/4 conditiona c d | ||||||||||||
Yes | 26.5 | 40.9 | 22.9 | 23.0 | 32.8 | 29.8 | 26.4 | 37.5 | 15.6 | 26.7 | 42.5 | 23.0 |
No | 73.5 | 59.1 | 77.1 | 77.0 | 67.2 | 70.2 | 73.6 | 62.5 | 84.4 | 73.3 | 57.5 | 77.0 |
Abbreviations: HS or less, some high school or high school graduate; HS + some college, high school graduate with either some college courses or other training; CNS, central nervous system tumor; HL, Hodgkin lymphoma; NHL, Non-Hodgkin lymphoma
Note: Percentages are based upon the total with available data for each variable
P<.05 from test of equality across the three insurance categories among all survivors.
P<.05 from test of equality across the three insurance categories among Black survivors.
P<.05 from test of equality across the three insurance categories among Hispanic survivors.
P<.05 from test of equality across the three insurance categories among White survivors.